René J Boosman

7PUBLICATIONS
4CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modellingPharmacogenomicsMortalityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 17, 2025
Evaluation of Aciclovir-Induced Nephrotoxicity in Critically Ill Patients: A Propensity-Matched Cohort Study.

René J Boosman, Rob J Bosman, Peter H J van der Voort

|Nov 22, 2022
Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial.

Nikki de Rouw, René J Boosman, Jacobus A Burgers

|Sep 02, 2022
Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof-of-concept study.

René J Boosman, Nikki de Rouw, Alwin D R Huitema

|Apr 15, 2022
Is age just a number? A population pharmacokinetic study of gemcitabine.

René J Boosman, Marie-Rose B S Crombag, Nielka P van Erp

|Mar 30, 2022
Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib.

René J Boosman, Cornedine J de Gooijer, Stefanie L Groenland

|Dec 11, 2021
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer.

René J Boosman, Jacobus A Burgers, Egbert F Smit

Pageof 2